Previous studies have demonstrated the association of elevated FOXR2 expression with poor prognosis in some cancers.10–12 However, whether FOXR2 overexpression has implications for therapeutic responses and clinical outcomes in specific CNS tumor types remains unknown. This evidence concerns the gene FOXR2 and cancer.